Neurelis to Join Sofie's Journey: Epilepsy Awareness Day at Disneyland Resort

Neurelis Participates in Sofie's Journey Epilepsy Awareness Day

Neurelis, Inc., known for its innovative product VALTOCO® (diazepam nasal spray), is excited to announce its participation in the 13th Annual Sofie's Journey Epilepsy Awareness Day and Education Expo at Disneyland Resort. This significant event is one of the largest gatherings for individuals affected by epilepsy, care partners, and healthcare professionals, aiming to foster a deeper understanding of epilepsy and its challenges.

Event Details

Scheduled for November 10th and 11th, 2025, the expo will take place at the Disneyland Hotel Convention Center from 9:00 AM to 5:00 PM PT. This event coincides with November's National Epilepsy Awareness Month, a time dedicated to raising awareness and improving education surrounding this condition. Following the expo, Epilepsy Awareness Day will occur on November 12th, allowing families to enjoy a day at the park together.

Community Engagement

"The EADDL offers a remarkable opportunity for individuals to unite and advocate for seizure awareness while finding support in a community that understands the unique difficulties of living with epilepsy," shared Lowell, a Neurelis Ambassador and an active adult living with epilepsy. As the regional director of an epilepsy foundation, he will represent Neurelis at the event, sharing his personal journey and expressing the importance of awareness in managing epilepsy.

Lowell is also set to sponsor a presentation at the expo, where he will discuss his experiences with VALTOCO, an FDA-approved treatment for frequent seizure episodes in patients aged two and older. His talk is scheduled for November 11th from 11:00 to 11:30 AM, following which attendees will have an opportunity to engage in a Q&A session.

Additionally, Neurelis will feature its ambassador Esteban, a resilient college graduate, who overcame significant challenges, including surgery and medication adjustments, to regain control of his life. Esteban will speak at a family dinner on November 10th, which is co-sponsored by the Epilepsy Alliance of America. "Initially diagnosed with epilepsy, I felt isolated, and it was a challenge to regain my independence. But thanks to VALTOCO, I have mastered my condition and I’m eager to share my journey to empower others facing similar obstacles," Esteban remarked.

Neurelis's Commitment

Craig Chambliss, Neurelis Founder and CEO, stated, "Our mission is to help individuals with epilepsy lead fulfilling lives. We are honored to participate in this event and connect with a community that we seek to support through our everyday efforts." Neurelis has a commitment to improving care for individuals with neurological disorders and is determined to raise awareness about epilepsy through initiatives like this expo.

About Neurelis

Founded on the principles of serving patients with high unmet medical needs, Neurelis develops and commercializes therapeutics for epilepsy and related neurological disorders. VALTOCO, a proprietary formulation of diazepam, is indicated for the acute treatment of episodic seizure activity, supporting both children and adults. The company’s focus on innovative therapies further extends to the development of NRL-1004, an investigational treatment for acute agitation associated with schizophrenia and bipolar disorder, as well as NRL-1049, aimed at treating cerebral cavernous malformations, a rare CNS disorder.

For additional information about VALTOCO and Neurelis’s ongoing initiatives, please visit VALTOCO's Official Website and Neurelis Medical Affairs.

Important Safety Information about VALTOCO

VALTOCO is an important treatment option but must be used carefully, particularly in conjunction with opioids, due to the potential for respiratory depression and sedation. Users should also be advised of the risks of misuse and withdrawal. Always consult with healthcare providers for a tailored approach to managing epilepsy effectively.